Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989759 | 0.85 | ACE (0.48) | ACE | |
| SCHEMBL25950518 | 0.82 | NOD1 (0.50) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL25950508 | 0.81 | NOD1 (0.43) | NOD1FOLH1GNPATACE | |
| SCHEMBL25950506 | 0.78 | NOD1 (0.42) | NOD1FOLH1GNPATFNTAFNTB | |
| SCHEMBL22280193 | 0.78 | ACE (0.39) | NOD1FOLH1GNPATACE | |
| SCHEMBL11553104 | 0.77 | NOD1 (0.47) | NOD1ACESLC6A5FNTAFNTB | |
| SCHEMBL15451409 | 0.76 | NOD1 (0.50) | NOD1FOLH1GNPATACE | |
| SCHEMBL20122349 | 0.76 | NOD1 (0.76) | NOD1FOLH1GNPAT | |
| SCHEMBL20287869 | 0.74 | NOD1 (0.43) | NOD1ACE | |
| SCHEMBL15846336 | 0.73 | FOLH1 (0.64) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | NOD1 65/4885FOLH1 60/4885GNPAT 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.